Indian pharmaceutical major Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market its anti-viral injection USP Acyclovir in that country.

The Ahmedabad headquartered company will market Acyclovir for injection USP, which is used to treat infections caused by herpes viruses, such as genital herpes, cold sores, shingles and chicken pox, in strengths of 500 mg/vial and 1000 mg/vial.
It will be produced at Zydus Cadila’s formulations manufacturing plant at Moraiya, Ahmedabad.

Zydus Cadila, which discovers, develops, manufactures and markets a broad range of healthcare products, has now more than 120 approvals to its credit and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since 2003-04.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.